Top 10 Pharmaceutical Companies in USA 2024
This article provides a detailed overview of the Top 10 Pharmaceutical Companies in USA 2024.
The pharmaceutical industry of United States is a significant part in global healthcare by developing innovative drugs, biologics, and medical solutions. With cutting-edge research, advanced manufacturing capabilities, and a strong regulatory framework, American pharmaceutical companies lead the world in drug discovery, export, and market expansion focusing on their establishment, product portfolio, export capabilities, revenue growth, flagship brands, and accreditations.
1. Merck & Co., Inc.
Merck maintained its leading position with strong sales from its cancer immunotherapy drug, Keytruda, which saw a 16% increase, reaching $7.3 billion in sales. The company also launched Winrevair for pulmonary arterial hypertension, contributing $70 million in its debut quarter.
Established: 1891
Headquarters: Rahway, New Jersey, USA
Total Products: More than 300, including vaccines, oncology drugs, and chronic disease medications.
Export Facilities: Operations in over 140 countries.
Total Revenue (2024): $63.9 billion
Growth Rate: +6.20 %
Market Share: (10.50%), Major contributor to vaccine and cancer treatment markets.
Flagship Products: Keytruda (immunotherapy), Gardasil (HPV vaccine), Januvia (diabetes treatment).
Accreditations: FDA, EMA, WHO-GMP, ISO certifications.
2. Pfizer Inc.
Pfizer reported a 2% revenue increase to $13.283 billion in Q2 2024, driven by its oncology segment and products from the Seagen acquisition. Despite a decline in COVID-19 product sales, other drugs like Vyndaqel saw significant growth. The company raised its full-year revenue guidance to $59.5-62.5 billion.
Established: 1849
Headquarters: New York, USA
Total Products: Over 500, including vaccines, biologics, and prescription drugs.
Export Facilities: Global distribution in over 125 countries.
Total Revenue (2024): Approximately $ 62.5 billion
Growth Rate: +6.8 %
Market Share: (10.3 %), One of the top pharmaceutical companies worldwide.
Flagship Products: Comirnaty (COVID-19 vaccine), Prevnar (pneumococcal vaccine), Eliquis (anticoagulant).
Accreditations: FDA, EMA, WHO-GMP, MHRA, ISO certifications.
3. Johnson & Johnson (Janssen Pharmaceuticals)
Johnson & Johnson‘s pharmaceutical segment achieved 4% growth, driven by key products such as Darzalex for multiple myeloma and Stelara for immune-mediated inflammatory diseases. The company continues to focus on innovative medicines and consumer health products
Established: 1886
Headquarters: New Brunswick, New Jersey, USA
Total Products: Over 250, including pharmaceuticals, consumer healthcare, and medical devices.
Export Facilities: Active in over 150 countries.
Total Revenue (2024): $58.35 billion
Growth Rate: +6.6%
Market Share: (9.6 %), A leading player in both pharmaceuticals and healthcare products.
Flagship Products: Stelara (immunology), Imbruvica (oncology), Xarelto (anticoagulant).
Accreditations: FDA, EMA, WHO-GMP, ISO certifications.
4. Eli Lilly and Company
Eli Lilly experienced substantial growth, primarily due to the success of its GLP-1 drug, Mounjaro, for Type 2 diabetes, with global sales reaching $5.3 billion in 2023 and a projected $12.3 billion for 2024. The FDA’s approval of Zepbound for obesity treatment further bolstered its market position.
Established: 1876
Headquarters: Indianapolis, Indiana, USA
Total Products: Over 150, specializing in diabetes, oncology, and neuroscience.
Export Facilities: Present in over 125 countries.
Total Revenue (2024): $45.7 billion
Growth Rate: +33.9 %
Market Share: (7.5 %), Leading in diabetes and obesity management.
Flagship Products: Trulicity (diabetes), Zepbound (weight loss), Verzenio (breast cancer treatment).
Accreditations: FDA, EMA, WHO-GMP, ISO certifications.
5. AbbVie Inc.
AbbVie reported consistent growth, with approximately 5% revenue increase. The company’s acquisitions of ImmunoGen and Cerevel Therapeutics are expected to strengthen its oncology and neuroscience portfolios.
Established: 2013 (Spun off from Abbott Laboratories)
Headquarters: North Chicago, Illinois, USA
Total Products: Over 150, specializing in immunology, oncology, and neuroscience.
Export Facilities: Global reach in more than 100 countries.
Total Revenue (2024): $47.44 billion
Growth Rate: +5.4 %
Market Share: (7.8 %), Leading in immunology and aesthetics.
Flagship Products: Humira (arthritis treatment), Botox (cosmetic and medical use), Rinvoq (autoimmune diseases).
Accreditations: FDA, EMA, WHO-GMP, MHRA, ISO certifications.
6. Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb maintained steady growth, driven by its diversified pharmaceutical portfolio. The company continues to focus on expanding its product offerings in oncology and immunology.
Established: 1858
Headquarters: New York, USA
Total Products: Over 200, focusing on oncology, cardiovascular, and immunology drugs.
Export Facilities: Operates in more than 130 countries.
Total Revenue (2024): $47.44 billion
Growth Rate: +5.4 %
Market Share: (7.8 %), A leader in cancer and immunotherapy treatments.
Flagship Products: Opdivo (cancer immunotherapy), Eliquis (anticoagulant), Revlimid (multiple myeloma).
Accreditations: FDA, EMA, WHO-GMP, ISO certifications.
7. Amgen Inc.
Amgen reported a 24% increase in product sales during Q3 2024, with ten products achieving double-digit growth. The acquisition of Horizon Therapeutics significantly bolstered its revenue, contributing $914 million in the first quarter of 2024.
Established: 1980
Headquarters: Thousand Oaks, California, USA
Total Products: Over 100, focusing on biotechnology-based treatments.
Export Facilities: Operations in more than 100 countries.
Total Revenue (2024): $33.3 billion
Growth Rate: +18.1 %
Market Share: (5.5 %), A leader in biotechnology and biosimilars.
Flagship Products: Enbrel (arthritis), Prolia (osteoporosis), Repatha (cholesterol treatment).
Accreditations: FDA, EMA, WHO-GMP, ISO certifications.
8. Gilead Sciences Inc.
Gilead Sciences achieved 7% growth in Q3 2024, with key products like Biktarvy for HIV treatment growing by 13%. The company continues to focus on expanding its antiviral and oncology portfolios.
Established: 1987
Headquarters: Foster City, California, USA
Total Products: Specializes in antiviral medications, including HIV, hepatitis, and COVID-19 treatments.
Export Facilities: Global supply in over 90 countries.
Total Revenue (2024): $27.95 billion
Growth Rate: +3.1 %
Market Share: (4.6 %), A major player in infectious disease therapeutics.
Flagship Products: Biktarvy (HIV treatment), Veklury (COVID-19 antiviral), Harvoni (hepatitis C treatment).
Accreditations: FDA, EMA, WHO-GMP, ISO certifications.
9. Regeneron Pharmaceuticals Inc.
Regeneron reported 11% year-over-year growth in Q3 2024, with strong performance from Dupixent, which saw a 23% increase in sales to $3.82 billion. The company continues to advance its pipeline in immunology and oncology.
Established: 1988
Headquarters: Tarrytown, New York, USA
Total Products: Focus on monoclonal antibodies for various diseases.
Export Facilities: Active in over 80 countries.
Total Revenue (2024): $13.85 billion
Growth Rate: +5.6 %
Market Share: (2.3 %), Strong presence in immunology and ophthalmology.
Flagship Products: Eylea (eye disease), Dupixent (eczema and asthma), Regen-Cov (COVID-19 antibody therapy).
Accreditations: FDA, EMA, WHO-GMP, ISO certifications.
10. Biogen
Biogen saw growth driven by its neurology-focused treatments, including therapies for multiple sclerosis and spinal muscular atrophy. The company is investing in expanding its pipeline in neurodegenerative diseases.
Established: 1978
Headquarters: 225 Binney Street, Cambridge, Massachusetts, USA
Total Products: Biogen has developed a range of therapies, particularly focusing on neurological and neurodegenerative diseases.
Multiple Sclerosis (MS) Treatments: Avonex (interferon beta-1a), Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Plegridy (peginterferon beta-1a), Vumerity (diroximel fumarate)
Spinal Muscular Atrophy (SMA) Treatment: Spinraza (nusinersen)
Alzheimer’s Disease Treatment: Aduhelm (aducanumab)
Biosimilars: Benepali (etanercept biosimilar), Imraldi (adalimumab biosimilar), Flixabi (infliximab biosimilar)
Export Facilities: Biogen operates manufacturing and distribution facilities in several countries to support its global operations. Notably, the company has a state-of-the-art facility in Solothurn, Switzerland, and another in North Carolina, USA, which are integral to its production and distribution network.
Total Revenue (2024): $12.45 billion
Growth Rate: +4.2 %
Market Share: (2.0 %), Biogen is recognized as a major player in the biotechnology sector, particularly in the treatment of multiple sclerosis and spinal muscular atrophy.
Flagship Products: Avonex, Tecfidera (for relapsing forms of multiple sclerosis), Spinraza (for spinal muscular atrophy), Aduhelm (for Alzheimer’s disease).
Accreditations: GMP, FDA, EMA, The company has also been recognized for its commitment to sustainability and corporate responsibility, being listed on the Dow Jones Sustainability World Index.
biogen.com
Conclusion
The U.S. pharmaceutical industry in 2024 has been characterized by strategic acquisitions, innovative product launches, and a focus on expanding therapeutic portfolios. Companies like Eli Lilly and Merck have demonstrated significant growth through successful drug developments and approvals, while others have strengthened their market positions via strategic acquisitions and diversification into new therapeutic areas.